Rentschler Commissions 2000-L Single-Use Bioreactor
Rentschler Biotechnologie launches 2000-L single-use bioreactor and announces additional expansion.
Rentschler Biotechnologie, a contract manufacturing and development organization for biopharmaceuticals, announced on March 23 that the company’s 2000-L single-use bioreactor has been put into operation.
The bioreactor, built and commissioned in six months, doubles the company’s single-use manufacturing capabilities and integrates in the existing manufacturing suites by supplementing two existing 1000-L single-use bioreactors, according to a company statement.
Rentschler has more than five years’ experience with single-use bioreactors and features a facility with a flexible space concept and movable equipment.
Rentschler also announced that the company will invest €24 million to build a system with two 3,000-L stainless steel bioreactors.
Source: Rentschler Biotechnologie
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
